Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 26, 2025
Join us in spotlighting milestone moments for companies in Qiming Venture Partners' portfolio.
Editor's Note: The "Qiming Weekly" column is published regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take deserves to be documented. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we invite you to join us in marking the milestone moments of our portfolio companies.
Major Partnerships
01/
Shangyue Technology Helps Feihe Group's Procurement Digitalization Platform Go Live
Recently, the procurement digitalization platform built by Shangyue Technology, a Qiming Venture Partners portfolio company, for Feihe Group officially launched. The platform comprehensively addresses Feihe Group's procurement management pain points, reshapes the entire procurement process, and builds an efficient, transparent, and intelligent new procurement system for the group.
The platform unifies control over production and non-production procurement, achieving systematic and standardized management that makes procurement operations rule-based and efficiently compliant. It enables online collaboration among requesters, purchasers, and suppliers, with full-process tracking, traceability, and auditability, plus anytime approval — significantly improving procurement compliance. From request submission to reconciliation and settlement, the entire process is digitized, substantially boosting procurement efficiency. Real-time data dashboards intuitively display daily procurement progress, system operations status, supplier performance, and other key metrics, providing clear data support for enterprise decision-making. Multiple configurable automation rules reduce manual intervention, driving Feihe Group's procurement management to become more convenient and efficient through business intelligence.
02/
BiTree Biotech and Sichuan Agricultural University College of Food Science Reach Strategic Partnership
Recently, the College of Food Science at Sichuan Agricultural University and BiTree Biotech, a Qiming Venture Partners portfolio company, jointly signed a strategic cooperation agreement. Guided by the principles of "resource sharing, mutual benefit and consensus, deepened cooperation, and joint development," this partnership will focus on applying BiTree Biotech's advanced omics technology platform to frontier areas of food science, conducting comprehensive and in-depth university-enterprise collaboration to jointly drive innovation in scientific research.
Both parties will deepen collaborative research in metabolomics, proteomics, genomics, and bioinformatics analysis. Leveraging each other's advantageous platforms and channels, they will tackle experimental bottlenecks on topics and research directions of mutual interest, providing solid technical support for high-level scientific research. Integrating their research capabilities, they will use omics technologies to deeply explore the functional bioactive substances in Ya'an Tibetan tea from Sichuan Province and their related mechanisms of action, enhancing scientific research value and opening new pathways for fundamental research on food functional components.
R&D Progress
01/
Peking Union Medical College Hospital Team Develops CAMPS II Technology Berry Genomics Collaboration Published in International Journal
Recently, a team led by Professor Juntao Liu at Peking Union Medical College Hospital and Berry Genomics (000710.SZ), a Qiming Venture Partners portfolio company, published significant research in the authoritative endocrinology and metabolism journal Journal of Inherited Metabolic Disease. Addressing the genetic diagnosis challenges of mucopolysaccharidosis type II (MPS II), the team developed CAMPS II technology based on third-generation HiFi long-read sequencing for the first time, enabling single-test precise detection of all variant types in the IDS gene that causes MPS II.
The CAMPS II technology developed in this study significantly improves diagnostic efficiency and accuracy while reducing diagnostic cost and time. With broader clinical application, this technology is expected to bring new breakthroughs in early precise diagnosis, treatment, and genetic counseling for MPS II, creating PGT-M opportunities to block genetic transmission for more patient families, and ultimately advancing effective genetic prevention and control of MPS II.
02/
CanSinoBIO Recombinant Trivalent Polio Vaccine Receives Clinical Trial Approval
Recently, CanSinoBIO (688185.SH, 06185.HK), a Qiming Venture Partners portfolio company, received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for its recombinant trivalent polio vaccine (Sf-RVN cell) (hereinafter referred to as the "recombinant polio vaccine"), authorizing clinical trials for prevention of polio caused by type I, II, and III poliovirus infections.
CanSinoBIO's recombinant polio vaccine is produced through protein structure design and VLP assembly technology, contains no viral genetic material, and does not rely on live virus during production and testing, with expected favorable safety and immunogenicity. The non-infectious VLP technology route for polio vaccines is recommended by the World Health Organization as one of the preferred vaccines for future polio eradication, with potential to contribute to global polio elimination.
03/
Guangdong Provincial People's Hospital Professor Xin Li's Team Collaborates with BiTree Biotech Publishes Paper in Renowned International Academic Journal
Recently, Professor Xin Li's team from the Emergency Department of Guangdong Provincial People's Hospital, a Guangdong medical aid expert in Tibet, once again led a collaboration with researcher Zhipeng Liu's team from Shanghai BiTree Metabolomics Technology Research Center (under BiTree Biotech, a Qiming Venture Partners portfolio company), Linzhi People's Hospital, and multiple other institutions to publish a paper in the renowned international academic journal Virulence (a top-tier CAS Q1 journal, impact factor/JCR quartile: 5.4/Q1).
The study shows that moderate-altitude exposure affects the gut bacteriome and phageome more than the gut mycobiome and archaeome in healthy individuals. Correlation analysis revealed that the intra- and inter-kingdom correlation networks of the gut multi-kingdom microbiome in healthy individuals at baseline were denser than after moderate-altitude exposure. Additionally, multiple statistical analyses indicate that changes in the gut multi-kingdom microbiome under moderate-altitude exposure in healthy individuals are significantly and strongly correlated with metabolic changes in blood glucose and short-chain fatty acids. These findings suggest that modulating the gut multi-kingdom microbiome could serve as a potential alternative therapeutic approach for improving abnormal blood glucose and related metabolic diseases.
Product Launch
Clinflash Launches Smart Recognition and Import Feature for Clinflash EDC
Recently, Clinflash, a Qiming Venture Partners portfolio company, announced that Clinflash EDC has launched a new smart recognition and import feature, which helps users significantly improve the efficiency and accuracy of LNR data entry.
With this feature, after users upload original data files such as PDFs and images, the system uses an OCR engine to recognize and extract text, table structures, and layout information, converting the recognition results into a universal text format. The system then automatically feeds the text into a built-in large language model, using prompt engineering to guide the model in extracting the required field information, parsing the output results, and importing them into the LNR configuration module of the EDC system.
Tech Strength
01/
WeRide Launches Fully Driverless Robobus Operations in Singapore
Recently, WeRide (NASDAQ: WRD), a Qiming Venture Partners portfolio company, announced that its autonomous mini-bus Robobus has begun fully driverless operations at Resorts World Sentosa (RWS) in Singapore, becoming the first autonomous vehicle in Southeast Asia to operate with "no safety driver on board."
This breakthrough marks a new stage in WeRide's technology validation and commercial deployment in Singapore. Since June 2024, WeRide's autonomous mini-bus has safely transported tens of thousands of passengers and efficiently completed thousands of autonomous shuttle services at RWS Sentosa. Building on this track record, after rigorous remote operations testing, road testing, and safety assessments, WeRide received approval from Singapore's Land Transport Authority (LTA) to officially launch fully driverless shuttle services to the public.
Li Xuan, CFO and Head of International Business at WeRide, said: "The launch of fully driverless Robobus operations in Singapore is a milestone for WeRide and for the development of smart mobility in Southeast Asia. It fully demonstrates the maturity of WeRide's autonomous driving technology in terms of safety, reliability, and scalable deployment. The strong support from Singapore's regulators and close collaboration with local partners have been crucial enablers of this milestone. This also reflects WeRide's enduring development philosophy — partnering with forward-looking governments and collaborators to bring autonomous driving technology into real life."
02/
UBTECH's Walker S2 Achieves World's First Autonomous Battery Swap
Recently, UBTECH (09880.HK), a Qiming Venture Partners portfolio company, announced that its next-generation industrial humanoid robot Walker S2 has achieved the world's first hot-swappable autonomous battery replacement system for humanoid robots — requiring no human intervention or shutdown, with a three-minute ultra-fast autonomous battery swap that gives Walker S2 uninterrupted working capability.
The core of the humanoid robot hot-swappable autonomous battery system lies in allowing the robot to autonomously complete battery replacement without shutting down or human intervention. On one hand, this avoids task interruptions caused by charging downtime, giving humanoid robots continuous operation capability. On the other hand, autonomous battery swapping reduces human maintenance costs and improves overall production efficiency.
In practical applications, the robot can autonomously choose to swap or charge batteries based on task priority, enabling dynamic energy management. The hot-swap technology features physical isolation and rapid power-cut mechanisms to prevent electric shock and explosion. Meanwhile, the dual-battery system enables seamless switching when the main battery fails, ensuring critical task execution — thereby achieving redundant backup and enhancing the safety and reliability of humanoid robots during factory operations.
03/ UBTECH AI-Driven Humanoid Robot Development Case Study Selected for Harvard Business School Case Library
Recently, the teaching case "UBTECH: AI-Driven Humanoid Robots" — authored by Professor Li Qi and Professor Zhang Bohui of The Chinese University of Hong Kong (Shenzhen) School of Management and Economics, together with Professor Zhang Letian of Harvard University, and a research team from The Chinese University of Hong Kong (Shenzhen) School of Management and Economics — was accepted into the Harvard Business School Publishing case library. Learners worldwide can now explore the humanoid robot development strategy and path choices of UBTECH (09880.HK), a Qiming Venture Partners portfolio company, through this case.
Using UBTECH as their research subject, the three professors conducted in-depth investigation and analysis, systematically explaining how UBTECH precisely positioned itself in the fiercely competitive technology sector to drive innovation in humanoid robot technology. They also deeply analyzed the challenges and response strategies UBTECH faced in market expansion. The case features rich content and rigorous logic, presenting to domestic and international readers the development path and strategic choices of a Chinese technology enterprise in the AI era.
04/ Hesai Technology Receives Certificate as LiDAR Leader in China's Robotic Lawn Mower Industry
Recently, Hesai Technology (NASDAQ: HSAI), a Qiming Venture Partners portfolio company, was awarded the "China Robotic Lawn Mower Industry LiDAR Leader" certificate by CETA Research, a third-party data statistics and consulting analysis institution for China's intelligent technology innovation industry.
The JT series is Hesai Technology's miniaturized ultra-hemispherical 3D LiDAR specifically designed for robotics and industrial applications. It has achieved significant breakthroughs in the robotic lawn mower market, enabling intelligent mowers to easily complete mapping, precise positioning, and agile obstacle avoidance with its compact form factor and outstanding 3D environmental perception capabilities — comprehensively upgrading the lawn care experience.
05/ 52TOYS Showcases "Super Activated" Series at China Pavilion, Osaka Expo
Recently, 52TOYS, a Qiming Venture Partners portfolio company, brought its "Super Activated" series to the China Pavilion at the Osaka Expo, participating in an event themed "Silk Whispers and Harmonies: Enjoying the Green Beauty of Shaanxi."
Designed with the concept of "transcending tradition, activating history, and passing on culture," the "Super Activated" series has long-standing ties to Shaanxi Province. In 2018, 52TOYS and the Shaanxi History Museum announced a partnership to launch the Shaanxi History Museum's Second Cultural and Creative Design Competition and 52TOYS' Third Prototype Design Competition — "Super Activated Artifacts." The "Super Activated Bronze Squad" products that 52TOYS showcased at the Osaka Expo originated from this competition. These toys, born from bronze artifacts, abandon their solemn image to present humorous and playful poses.
06/ Weikang Probiotics' Bifidobacterium animalis subsp. lactis BLa80 Receives Dual FDA GRAS Certification
Bifidobacterium animalis subsp. lactis BLa80 from Weikang Probiotics, a Qiming Venture Partners portfolio company, has successfully passed both the FDA self-affirmed GRAS and FDA GRAS Notice dual certifications from the U.S. Food and Drug Administration (FDA), becoming the first strain from mainland China to receive genuine "dual GRAS" certification.
GRAS certification is the FDA's authoritative certification for food additive safety. Self-affirmed GRAS involves companies organizing expert teams to form their own recognition of a substance's safety, while FDA GRAS Notice represents a higher level of safety certification. Weikang Probiotics submitted to the FDA comprehensive data including ingredient information, toxicology tests, and production process validation. After multi-dimensional official review, it received the authoritative "no questions" conclusion. Through multi-dimensional professional review under "dual GRAS," BLa80 has become China's first strain certified to international high safety standards, marking that the safety and quality of the BLa80 strain have reached globally leading levels.
07/ Ark Biosciences' Ziresovir Added to WHO Priority List for Respiratory Syncytial Virus Drugs
The World Health Organization (WHO) and its Global Accelerator for Paediatric Formulations Network (GAP-f) recently released the Paediatric Antiviral Drug Optimization for Respiratory Syncytial Virus (PADO-RSV) Meeting Report. Ziresovir (10mg), an innovative antiviral drug for respiratory syncytial virus (RSV) developed by Qiming Venture Partners portfolio company Ark Biosciences, was officially added to the WHO PADO-RSV priority list for RSV therapeutics in children.
Ziresovir is the first and only RSV antiviral treatment to be included in this list. This also marks the first time WHO/GAP-f has included a China-developed anti-RSV drug in its paediatric drug optimization priority list, signaling that Ark Biosciences' innovations in paediatric anti-infective therapies have gained recognition from a leading international health authority, and highlighting Chinese innovative drugs' contributions to global public health.
08/ Rayner China Presents at the Chinese Medical Association's 25th Congress of Cataract and Refractive Surgery
During the Chinese Medical Association's 25th Congress of Cataract and Refractive Surgery, Qiming Venture Partners portfolio company Rayner China showcased its first domestically produced extended depth-of-focus (EDoF) intraocular lens Vision Infinity®, its full line of IOL products, and an eye massager. The company exchanged insights with domestic and international experts on the latest research in ophthalmology and vision science, shared clinical experience with its products, and discussed future product planning.
Additionally, Rayner Vision, a subsidiary of Rayner China, entered into a strategic partnership with Korean company SEODONG to introduce the NURIEYE eye massager. The device activates with one touch and uses three massage modes — heat, air pressure, and vibration — working in cycles to improve microcirculation around the eyes and relieve discomfort caused by visual fatigue.
09/ Regen Biotech's Absorbable Radioprotective Hydrogel for Cancer Radiotherapy Enters China's "Green Channel" for Innovative Medical Devices
The National Medical Products Administration's Center for Medical Device Evaluation recently released the Innovative Medical Device Special Review Application Review Results Announcement (No. 6 of 2025). Respacio®, an absorbable radioprotective hydrogel for cancer radiotherapy developed by Qiming Venture Partners portfolio company Regen Biotech, successfully passed the National Medical Products Administration's (NMPA) Class III innovative medical device special review application, officially entering the "green channel" of expedited review.
Respacio® can be implanted via minimally invasive injection between the tumor and the rectum, creating a stable separation space that significantly reduces radiation exposure to the rectum and other adjacent healthy tissues, thereby effectively lowering or preventing radiation-induced rectal injury.
10/ Qianmai Medical's Beijing Qianmai Forensic Identification Center Passes CMA On-Site Assessment
Qiming Venture Partners portfolio company Qianmai Medical announced that its subsidiary, Beijing Qianmai Medical Laboratory Co., Ltd. ("Beijing Qianmai"), has passed the on-site assessment for China Metrology Accreditation (CMA) for its forensic identification center.
The expert review panel conducted a comprehensive, in-depth, and rigorous "health check" of the center's management system, technical capabilities, facilities and environment, personnel quality, and operational quality. Drawing on the Criteria for the Assessment of Inspection and Testing Body Qualification and relevant laws and regulations, the experts evaluated the suitability, effectiveness, and continuous improvement of Beijing Qianmai Forensic Identification Center's quality management system through multiple methods including presentations, document reviews, on-site questioning, record verification, witnessed testing, and assessments of authorized signatories.
11/ Mindong Hospital in Ningde, Fujian Province Performs Surgery Using JST Medical's EPS® Total Knee Arthroplasty Robot
A team led by Director Wang Tihui at Mindong Hospital in Ningde, Fujian Province recently performed a total knee arthroplasty on a patient with 13° valgus knee deformity using the EPS® total knee arthroplasty robot developed by Qiming Venture Partners portfolio company JST Medical.
The procedure went smoothly, and the patient recovered well post-operatively with outcomes meeting expectations. The success of this complex case is a strong testament to JST Medical's deep expertise in precision navigation and robotic control, and validates the safety, accuracy, and efficiency of the EPS® total knee arthroplasty robot in addressing common complex deformities such as valgus knee.
12/ Bondent Opens Southwest China's First PPM Periodontal-Implant International Center in Kunming, Yunnan
The first "PPM Periodontal-Implant International Center" in southwest China was officially inaugurated in Kunming, Yunnan Province. This milestone marks a key step forward in Qiming Venture Partners portfolio company Bondent's national strategy to advance its PPM (Perio-Prosthetic Maintenance) periodontal-implant health management program.
Leveraging Bondent's comprehensive capabilities in digital-intelligent equipment, refined clinical techniques, and top-tier international academic resources, Aijie Yunya Dental became the first local platform in southwest China to host a PPM international center, driving the clinical practice and academic adoption of PPM principles in Yunnan.
13/ SuperView Technology Participates in the 15th China Life Science Public Platform Management and Technology Development Symposium
Qiming Venture Partners portfolio company SuperView Technology, a leader in domestic super-resolution microscopy, showcased its self-developed series of super-resolution microscopes at the 15th China Life Science Public Platform Management and Technology Development Symposium. The company presented its cutting-edge innovations and outstanding practical applications in super-resolution imaging technology to attendees.
On the exhibition floor, the HIS-SIM, SIM-Supreme, and Cell Xpanse ultra-high-resolution microscopes drew crowds. The HIS-SIM system offers precise insights for biomedical research through its superior performance and intelligent operation. The SIM-Supreme tackles complex multi-channel dynamic observation of cells with its dual-mode super-resolution capabilities in both fluorescence and label-free imaging. Cell Xpanse pushes the boundaries of cellular imaging, with its high-throughput, deep-sectioning features opening broader application prospects and leading multi-modal fluorescence super-resolution applications into a new dimension.
14/ Sinovision Supports County-Level Medical Alliance Construction in Sichuan
In early 2025, Qiming Venture Partners portfolio company Sinovision successfully won the bid for CT equipment in the Sichuan Province County-Level Medical Alliance Equipment Renewal and Construction Project, leveraging its technological innovation and overall capabilities. The rapid delivery, installation, and training of nine 64-slice CT units demonstrated Sinovision's strong project execution and delivery capacity.
Take Renshou County Hospital of Traditional Chinese Medicine, where Sinovision's equipment was installed through this centralized procurement, as an example. The hospital's new campus had previously been caught in a dilemma over equipment configuration: ultra-high-end devices carried prohibitive maintenance costs, while lower-end models suffered from tube overheating that compromised screening quality. Since the installation of Sinovision's InsitumCT 768 in April, the machine has handled roughly 200 examinations daily thanks to its strong performance. Comprehensive after-sales service has substantially reduced the hospital's long-term maintenance burden, allowing the equipment's full value to be realized.
Company Honors
01/
Nearly 10 Qiming Venture Partners Portfolio Companies Named in
2024 Beijing Digital Economy Benchmark Enterprises Report
The 2024 Beijing Digital Economy Benchmark Enterprises Report was officially released at a thematic forum of the 2025 Global Digital Economy Conference — the 2025 Industrial Internet Innovation and Development Forum. The selected benchmark enterprises not only serve as core growth engines but also demonstrate and drive the collective advancement of industrial chain partners, propelling high-quality development in the digital economy.
Qiming Venture Partners portfolio companies including Xiaomi (01810.HK), XSKY, Zhipu AI, Roborock (688169.SH), Shukun Technology, Yuanxin Technology, and DeepWise were among those selected.
02/
3 Qiming Venture Partners Portfolio Company Leaders Named to
2025 Forbes China Best CEOs List
The 2025 Forbes China Best CEOs List was recently unveiled. Forbes China evaluated CEOs based on a composite of metrics including market capitalization, stock price performance over the measurement period, net profit and growth rate, ROE, and other fundamental financial and shareholder return indicators, selecting the top 50 listed company CEOs by overall score.
Qiming Venture Partners portfolio company leaders on the list include Xiaomi (01810.HK) founder, executive director, chairman and CEO Lei Jun; MicroPort EP MedTech (688617.SH) general manager Chenghui Zheng; and Meitu (01357.HK) executive director, chairman and CEO Zeyuan Wu.
Past Issues
Qiming Weekly | Qiming Venture Partners Portfolio Funding and Updates Vol. 25, 2025 Speaker Lineup Revealed | Register Now for 2025 WAIC Qiming Venture Partners · Entrepreneurship and Investment Forum — Venture Capital Enters a Resonance Cycle of AI Technology and Applications
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in the Technology and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns in their respective industries.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ: WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, and Biren Technology.